Research
Hormonal
A growing number of new agents acting on incretin hormones are becoming available for clinical practice.
Clinicians should stay informed about new pharmacological options for treating obesity and T2DM.
StrongSupportsmedium confidence
A growing number of new agents acting on incretin hormones are becoming available for everyday clinical practice.
Why this rating
The abstract discusses the emergence of new pharmacological agents.
Source
New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists
Ferenc Sztanek et al. · Biomedicines · 2024
reviewCited 35×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →